Behind the science
Three facts scientists have learned about RSV – and why sharing them could help protect those most at risk
RSV is one of the most common seasonal respiratory viruses – yet until recently, its role in adult disease was not well known. GSK’s head of vaccines R&D and infectious disease research, Phil Dormitzer, shares what researchers have learned about RSV and how we’re using this knowledge to increase awareness. At IDWeek 2024, we’ll be sharing data highlighting our scientific developments in the prevention and treatment of infectious diseases like RSV.
Our purpose
We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology
Behind the science